How many times a year should tremelimumab be used for hepatocellular carcinoma?

A single high-dose tremelimumab plus durvalumab, an infusion regimen called STRIDE, showed encouraging clinical activity and safety in a Phase 2 trial in unresectable hepatocellular carcinoma. Hepatocellular carcinoma is one of the most common causes of cancer-related death worldwide. Most patients have advanced or metastatic disease at diagnosis or disease relapse after local intervention for therapeutic purposes and therefore require systemic therapy.

Hepatocellular carcinoma patients with body weight Patients with hepatocellular carcinoma whose body weight is ≥30kg should first receive a single dose of temsilimumab 300 mg intravenously on day 1 of the first cycle, then use durvalumab 1500 mg intravenously, and then continue to use a single dose of durvalumab 1500 mg intravenously every 4 weeks; weight Patients < 30 kg receive a single dose of 4 mg/kg IV temsitumumab and 20 mg/kg IV durvalumab on day 1 of cycle 1, followed by single doses of 20 mg/kg IV every 4 weeks until disease progression or unacceptable toxicity. Administration of both drugs generally does not require hospitalization.

Tesetumumab is an emerging cancer immunotherapy drug. It is a prescription drug and has not yet been launched in China. Therefore, it has not been included in the medical insurance list. Domestic patients cannot yet purchase this drug. The U.S. version of temsitumumab the original drug has been on the market overseas for a short time and is sold under the trade name Imjudo. The price is not yet clear, and there are currently no generic versions of temsitumumab produced and launched. For specific prices and drug details, please consult a medical consultant.